FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4242550747> ?p ?o ?g. }

• W4242550747 endingPage "457" @default.
• W4242550747 startingPage "451" @default.
• W4242550747 abstract "Sensor-augmented insulin pump therapy (SAPT) with low-glucose suspend (LGS) is an effective and safe alternative for treating patients with type 1 diabetes mellitus (T1DM). New predictive low-glucose management (PLGM) systems decrease the severity and duration of hypoglycemic events. However, evidence of benefits in patients previously treated with SAPT-LGS is limited. A prospective before-after study was conducted in patients with T1DM treated with SAPT-LGS, who were switched to the Minimed® 640G system with SmartGuard® to assess the impact on A1c levels, severe hypoglycemia (SH), hypoglycemia unawareness (HU), and area under the curve (AUC) <70 mg/dL after 3 months of follow-up. Fifty-five patients with T1DM with a mean age of 37.9 (IQR 6, 79) years and a mean baseline A1c level of 7.52 ± 1.11% were enrolled. After 3 months under PLGM, A1c levels significantly decreased to 7.18 ± 0.91% (p = 0.004). SH rate decreased from 2.47 (CI 0.44, 4.90) to 0.87 (CI 0.22, 1.52) events/patient-year (Incidence rate ratio 0.353, 95% CI 0.178, 0.637), AUC <70 mg/dL decreased from 0.59 ± 0.76 to 0.35 ± 0.65 mg/dL × min (p = 0.030). HU determined by Clarke questionnaire resolved in 23 out of 30 patients (p = 0.002). This study suggests that SAPT with PLGM decreases the frequency of SH, HU, exposure to glucose levels below 70 mg/dL, and A1c levels. Based on these results, this therapy should be considered in T1DM patients previously treated with SAPT-LGS with persistent SH and HU. Further clinical trials comparing the efficacy and safety of these features are required. La terapia con bomba de insulina integrada a sistema de monitoreo continuo con suspensión en hipoglucemia (SAPT-LGS) es una alternativa efectiva y segura para el tratamiento en pacientes con diabetes tipo 1 (DM1). La función de suspensión antes del límite bajo (PLGM) reduce la gravedad y la duración de los eventos hipoglucémicos. Sin embargo, la evidencia del beneficio en pacientes tratados previamente con SAPT-LGS es limitada. Se realizó un estudio longitudinal antes y después con pacientes DM1 tratados con SAPT-LGS que se cambiaron al sistema Minimed® 640G con SmartGuard®, con el fin de evaluar el impacto en los niveles de A1c, hipoglucemia severa (HS), hipoglucemia asintomática (HA) y área bajo la curva (AUC) <70 mg/dl después de tres meses de seguimiento. Se incluyeron 55 pacientes con DM1, de 37.9 (IQR 6, 79) años, A1c basal de 7.52 ± 1.11%. A los 3 meses bajo PLGM, la A1c se redujo significativamente a 7.18% ± 0.91% (p = 0.004). La tasa de HS se redujo de 2.47 (CI 0.44,4.90) a 0.87 (CI 0.22,1.52) eventos/año del paciente (índice de incidencia 0.353 IC 95%, 0.178, 0.637), el AUC <70 mg/dl se redujo de 0,59 ± 0,76 a 0,35 ± 0,65 mg/dl x minuto (p = 0,030). HA determinado por el cuestionario Clarke resolvió en 23 de 30 pacientes (p = 0,002). Este estudio sugiere que PLGM reduce la frecuencia de HS, HA, la exposición a niveles de glucosa por debajo de 70 mg/dl y A1c. Con base a estos resultados, esta terapia debería considerarse en pacientes con DM1 tratados previamente con SAPT-LGS que persisten con HS e HA. Se requieren ensayos clínicos adicionales que comparen la eficacia y la seguridad de estas características." @default.
• W4242550747 created "2022-05-12" @default.
• W4242550747 creator A5004043408 @default.
• W4242550747 creator A5006005548 @default.
• W4242550747 creator A5011147337 @default.
• W4242550747 creator A5012154437 @default.
• W4242550747 creator A5026587958 @default.
• W4242550747 creator A5029181254 @default.
• W4242550747 creator A5046466917 @default.
• W4242550747 creator A5049823946 @default.
• W4242550747 creator A5051345645 @default.
• W4242550747 creator A5068967159 @default.
• W4242550747 creator A5079772034 @default.
• W4242550747 date "2018-10-01" @default.
• W4242550747 modified "2023-10-18" @default.
• W4242550747 title "Efficacy and safety of sensor-augmented pump therapy (SAPT) with predictive low-glucose management in patients diagnosed with type 1 diabetes mellitus previously treated with SAPT and low glucose suspend" @default.
• W4242550747 doi "https://doi.org/10.1016/j.endien.2018.03.015" @default.
• W4242550747 hasPublicationYear "2018" @default.
• W4242550747 type Work @default.
• W4242550747 citedByCount "1" @default.
• W4242550747 countsByYear W42425507472021 @default.
• W4242550747 crossrefType "journal-article" @default.
• W4242550747 hasAuthorship W4242550747A5004043408 @default.
• W4242550747 hasAuthorship W4242550747A5006005548 @default.
• W4242550747 hasAuthorship W4242550747A5011147337 @default.
• W4242550747 hasAuthorship W4242550747A5012154437 @default.
• W4242550747 hasAuthorship W4242550747A5026587958 @default.
• W4242550747 hasAuthorship W4242550747A5029181254 @default.
• W4242550747 hasAuthorship W4242550747A5046466917 @default.
• W4242550747 hasAuthorship W4242550747A5049823946 @default.
• W4242550747 hasAuthorship W4242550747A5051345645 @default.
• W4242550747 hasAuthorship W4242550747A5068967159 @default.
• W4242550747 hasAuthorship W4242550747A5079772034 @default.
• W4242550747 hasConcept C120665830 @default.
• W4242550747 hasConcept C121332964 @default.
• W4242550747 hasConcept C126322002 @default.
• W4242550747 hasConcept C134018914 @default.
• W4242550747 hasConcept C188816634 @default.
• W4242550747 hasConcept C2779306644 @default.
• W4242550747 hasConcept C2779794567 @default.
• W4242550747 hasConcept C2780668416 @default.
• W4242550747 hasConcept C2781232474 @default.
• W4242550747 hasConcept C555293320 @default.
• W4242550747 hasConcept C61511704 @default.
• W4242550747 hasConcept C71924100 @default.
• W4242550747 hasConcept C90924648 @default.
• W4242550747 hasConceptScore W4242550747C120665830 @default.
• W4242550747 hasConceptScore W4242550747C121332964 @default.
• W4242550747 hasConceptScore W4242550747C126322002 @default.
• W4242550747 hasConceptScore W4242550747C134018914 @default.
• W4242550747 hasConceptScore W4242550747C188816634 @default.
• W4242550747 hasConceptScore W4242550747C2779306644 @default.
• W4242550747 hasConceptScore W4242550747C2779794567 @default.
• W4242550747 hasConceptScore W4242550747C2780668416 @default.
• W4242550747 hasConceptScore W4242550747C2781232474 @default.
• W4242550747 hasConceptScore W4242550747C555293320 @default.
• W4242550747 hasConceptScore W4242550747C61511704 @default.
• W4242550747 hasConceptScore W4242550747C71924100 @default.
• W4242550747 hasConceptScore W4242550747C90924648 @default.
• W4242550747 hasIssue "8" @default.
• W4242550747 hasLocation W42425507471 @default.
• W4242550747 hasOpenAccess W4242550747 @default.
• W4242550747 hasPrimaryLocation W42425507471 @default.
• W4242550747 hasRelatedWork W2007885393 @default.
• W4242550747 hasRelatedWork W2135273399 @default.
• W4242550747 hasRelatedWork W2354305788 @default.
• W4242550747 hasRelatedWork W2362888642 @default.
• W4242550747 hasRelatedWork W2585489026 @default.
• W4242550747 hasRelatedWork W2978975479 @default.
• W4242550747 hasRelatedWork W3023732669 @default.
• W4242550747 hasRelatedWork W3137046229 @default.
• W4242550747 hasRelatedWork W4207049476 @default.
• W4242550747 hasRelatedWork W4233779878 @default.
• W4242550747 hasVolume "65" @default.
• W4242550747 isParatext "false" @default.
• W4242550747 isRetracted "false" @default.
• W4242550747 workType "article" @default.